Low anterior resection syndrome (LARS) is also known as anterior resection syndrome. It’s a collection of bowel symptoms that can happen after surgery to remove all or part of your rectum. These ...

Today we’ve published our Annual Report and Accounts 2024, and it’s clear the year marks a turning point. When we launched our bold new five-year strategy in 2023, we knew it was ambitious, but ...

We're delighted to see the news that the National Institute for Health and Care Excellence (NICE) has approved the use of the drug fruquintinib (Fruzaqla) for eligible advanced bowel cancer patients ...

CaPP3 is the latest in a series of ground-breaking studies exploring how aspirin can help prevent bowel cancer in people with Lynch syndrome. It builds on the earlier CAPP2 trial, which showed that ...

We’re campaigning to improve the diagnosis and care of people with Lynch syndrome. As part of this work, we bought together academics, clinicians, and policymakers for a roundtable discussion to make ...

Bowel cancer is rising fast in under-50s. We're helping drive UK and global research to understand why — and what we can do to stop it. Bowel cancer is rising rapidly in people under 50 in the UK.

We’re disappointed to share the news that the Scottish Medicines Consortium (SMC) has not approved the use of fruquintinib (Fruzaqla®) to treat patients with advanced bowel cancer living in Scotland.

We’re proud to launch our new report, ‘Delivering the ambitions of the NHS Long Term Plan: a review of progress on bowel cancer in England’. The report looks at how the NHS Long Term Plan has made a ...

I have two grown up children; Lauren who is 26 and Owen who is 19. I’ve worked in hospitality, Housing and Social Care over the years, and up until my diagnosis, I had my own business which I started ...

Pelvic exenteration is a major operation that takes out some or all of the organs inside the pelvis. The pelvis is the lower part of the stomach (abdomen) between the hip bones (pelvic bones). It ...

The Scottish Medicines Consortium (SMC) has announced that they have approved trifluridine/tipiracil (Lonsurf) with bevacizumab (Avastin) for eligible patients living in Scotland. SMC’s decision means ...

Mr Jones, lead investigator for a trial looking at giving personalised cancer vaccines to people with bowel cancer, tells us more about this new treatment.